Literature DB >> 15357924

Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models.

Eric J Kunkel1, Ivan Plavec, Dat Nguyen, Jennifer Melrose, Elen S Rosler, Leon T Kao, Yuker Wang, Evangelos Hytopoulos, Anthony C Bishop, Raynard Bateman, Kevan M Shokat, Eugene C Butcher, Ellen L Berg.   

Abstract

Rapid, quantitative methods for characterizing the biological activities of kinase inhibitors in complex human cell systems could allow the biological consequences of differential target selectivity to be monitored early in development, improving the selection of drug candidates. We have previously shown that Biologically Multiplexed Activity Profiling (BioMAP) permits rapid characterization of drug function based on statistical analysis of protein expression data sets from complex primary human cellbased models of disease biology. Here, using four such model systems containing primary human endothelial cells and peripheral blood mononuclear cells in which multiple signaling pathways relevant to inflammation and immune responses are simultaneously activated, we demonstrate that BioMAP analysis can detect and distinguish a wide range of inhibitors directed against different kinase targets. Using a panel of p38 mitogen-activated protein kinase antagonists as a test set, we show further that related compounds can be distinguished by unique features of the biological responses they induce in complex systems, and can be classified according to their induction of shared (on-target) and secondary activities. Statistical comparisons of quantitative BioMAP profiles and analysis of profile features allow correlation of induced biological effects with chemical structure and mapping of biological responses to chemical series or substituents on a common scaffold. Integration of automated BioMAP analysis for prioritization of hits and for structure-activity relationship studies may improve and accelerate the design and selection of optimal therapeutic candidates.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15357924     DOI: 10.1089/adt.2004.2.431

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  20 in total

1.  A selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiation.

Authors:  Giovanna Bergamini; Kathryn Bell; Satoko Shimamura; Thilo Werner; Andrew Cansfield; Katrin Müller; Jessica Perrin; Christina Rau; Katie Ellard; Carsten Hopf; Carola Doce; Daniel Leggate; Raffaella Mangano; Toby Mathieson; Alison O'Mahony; Ivan Plavec; Faiza Rharbaoui; Friedrich Reinhard; Mikhail M Savitski; Nigel Ramsden; Emilio Hirsch; Gerard Drewes; Oliver Rausch; Marcus Bantscheff; Gitte Neubauer
Journal:  Nat Chem Biol       Date:  2012-04-29       Impact factor: 15.040

2.  An efficient rapid system for profiling the cellular activities of molecular libraries.

Authors:  Jonathan S Melnick; Jeff Janes; Sungjoon Kim; Jim Y Chang; Daniel G Sipes; Drew Gunderson; Laura Jarnes; Jason T Matzen; Michael E Garcia; Tami L Hood; Ronak Beigi; Gang Xia; Richard A Harig; Hayk Asatryan; S Frank Yan; Yingyao Zhou; Xiang-Ju Gu; Alham Saadat; Vicki Zhou; Frederick J King; Christopher M Shaw; Andrew I Su; Robert Downs; Nathanael S Gray; Peter G Schultz; Markus Warmuth; Jeremy S Caldwell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

Review 3.  Cellular assays as portals to seven-transmembrane receptor-based drug discovery.

Authors:  Terry P Kenakin
Journal:  Nat Rev Drug Discov       Date:  2009-07-17       Impact factor: 84.694

4.  Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms.

Authors:  Nicole C Kleinstreuer; Jian Yang; Ellen L Berg; Thomas B Knudsen; Ann M Richard; Matthew T Martin; David M Reif; Richard S Judson; Mark Polokoff; David J Dix; Robert J Kavlock; Keith A Houck
Journal:  Nat Biotechnol       Date:  2014-05-18       Impact factor: 54.908

5.  Ras-mutant cancers are sensitive to small molecule inhibition of V-type ATPases in mice.

Authors:  Bhairavi Tolani; Anna Celli; Yanmin Yao; Yong Zi Tan; Richard Fetter; Christina R Liem; Adam J de Smith; Thamiya Vasanthakumar; Paola Bisignano; Adam D Cotton; Ian B Seiple; John L Rubinstein; Marco Jost; Jonathan S Weissman
Journal:  Nat Biotechnol       Date:  2022-07-25       Impact factor: 68.164

Review 6.  Phenotypic drug discovery: recent successes, lessons learned and new directions.

Authors:  Fabien Vincent; Arsenio Nueda; Jonathan Lee; Monica Schenone; Marco Prunotto; Mark Mercola
Journal:  Nat Rev Drug Discov       Date:  2022-05-30       Impact factor: 112.288

7.  Drug discovery in psychiatric illness: mining for gold.

Authors:  Greg I Elmer; Neri Kafkafi
Journal:  Schizophr Bull       Date:  2009-03-18       Impact factor: 9.306

Review 8.  Connecting synthetic chemistry decisions to cell and genome biology using small-molecule phenotypic profiling.

Authors:  Bridget K Wagner; Paul A Clemons
Journal:  Curr Opin Chem Biol       Date:  2009-10-12       Impact factor: 8.822

9.  Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects.

Authors:  Ellen L Berg; Mark A Polokoff; Alison O'Mahony; Dat Nguyen; Xitong Li
Journal:  Int J Mol Sci       Date:  2015-01-05       Impact factor: 5.923

10.  Org 214007-0: a novel non-steroidal selective glucocorticoid receptor modulator with full anti-inflammatory properties and improved therapeutic index.

Authors:  Marie-José C van Lierop; Wynand Alkema; Anke J Laskewitz; Rein Dijkema; Hans M van der Maaden; Martin J Smit; Ralf Plate; Paolo G M Conti; Christan G J M Jans; C Marco Timmers; Constant A A van Boeckel; Scott J Lusher; Ross McGuire; Rene C van Schaik; Jacob de Vlieg; Ruben L Smeets; Claudia L Hofstra; Annemieke M H Boots; Marcel van Duin; Benno A Ingelse; Willem G E J Schoonen; Aldo Grefhorst; Theo H van Dijk; Folkert Kuipers; Wim H A Dokter
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.